**Federal marijuana rescheduling from Schedule I to Schedule III advanced through executive and administrative action in 2026, shaping trader views on timing for broader changes.** In December 2025, President Trump issued an executive order directing expedited completion of the rulemaking process to move marijuana to Schedule III. On April 23, 2026 (effective April 28), the Department of Justice and DEA issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, while withdrawing prior proceedings and launching a new expedited hearing on full rescheduling of all marijuana. The DEA hearing, focused on evidence for transferring marijuana broadly to Schedule III, began June 29, 2026, and was scheduled to conclude no later than July 15, 2026. Post-hearing steps include potential issuance of a final rule, followed by a publication and effective-date period (typically 30 days or more under the Congressional Review Act for major rules). As of mid-August 2026, market pricing reflects trader assessments of whether these remaining procedural steps, any legal challenges, or further administration actions will meet specific resolution deadlines. Key upcoming catalysts include the DEA’s post-hearing determination and Federal Register publication timeline.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया$796,329 वॉल्यूम
31 मार्च, 2026
30 सितंबर
14%
31 दिसंबर
28%
$796,329 वॉल्यूम
30 सितंबर
$0 वॉल्यूम
14%
31 दिसंबर
$186,758 वॉल्यूम
28%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Federal marijuana rescheduling from Schedule I to Schedule III advanced through executive and administrative action in 2026, shaping trader views on timing for broader changes.** In December 2025, President Trump issued an executive order directing expedited completion of the rulemaking process to move marijuana to Schedule III. On April 23, 2026 (effective April 28), the Department of Justice and DEA issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, while withdrawing prior proceedings and launching a new expedited hearing on full rescheduling of all marijuana.
The DEA hearing, focused on evidence for transferring marijuana broadly to Schedule III, began June 29, 2026, and was scheduled to conclude no later than July 15, 2026. Post-hearing steps include potential issuance of a final rule, followed by a publication and effective-date period (typically 30 days or more under the Congressional Review Act for major rules). As of mid-August 2026, market pricing reflects trader assessments of whether these remaining procedural steps, any legal challenges, or further administration actions will meet specific resolution deadlines. Key upcoming catalysts include the DEA’s post-hearing determination and Federal Register publication timeline.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
बाज़ार खुला: Feb 7, 2026, 5:04 PM ET
वॉल्यूम
$796,329समाप्ति तिथि
31 मार्च, 2026बाज़ार खुला
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.**Federal marijuana rescheduling from Schedule I to Schedule III advanced through executive and administrative action in 2026, shaping trader views on timing for broader changes.** In December 2025, President Trump issued an executive order directing expedited completion of the rulemaking process to move marijuana to Schedule III. On April 23, 2026 (effective April 28), the Department of Justice and DEA issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, while withdrawing prior proceedings and launching a new expedited hearing on full rescheduling of all marijuana.
The DEA hearing, focused on evidence for transferring marijuana broadly to Schedule III, began June 29, 2026, and was scheduled to conclude no later than July 15, 2026. Post-hearing steps include potential issuance of a final rule, followed by a publication and effective-date period (typically 30 days or more under the Congressional Review Act for major rules). As of mid-August 2026, market pricing reflects trader assessments of whether these remaining procedural steps, any legal challenges, or further administration actions will meet specific resolution deadlines. Key upcoming catalysts include the DEA’s post-hearing determination and Federal Register publication timeline.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
वॉल्यूम
$796,329समाप्ति तिथि
31 मार्च, 2026बाज़ार खुला
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...**Federal marijuana rescheduling from Schedule I to Schedule III advanced through executive and administrative action in 2026, shaping trader views on timing for broader changes.** In December 2025, President Trump issued an executive order directing expedited completion of the rulemaking process to move marijuana to Schedule III. On April 23, 2026 (effective April 28), the Department of Justice and DEA issued a final order immediately placing FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, while withdrawing prior proceedings and launching a new expedited hearing on full rescheduling of all marijuana. The DEA hearing, focused on evidence for transferring marijuana broadly to Schedule III, began June 29, 2026, and was scheduled to conclude no later than July 15, 2026. Post-hearing steps include potential issuance of a final rule, followed by a publication and effective-date period (typically 30 days or more under the Congressional Review Act for major rules). As of mid-August 2026, market pricing reflects trader assessments of whether these remaining procedural steps, any legal challenges, or further administration actions will meet specific resolution deadlines. Key upcoming catalysts include the DEA’s post-hearing determination and Federal Register publication timeline.
Polymarket डेटा का संदर्भ देने वाला प्रयोगात्मक AI-जनरेटेड सारांश। यह ट्रेडिंग सलाह नहीं है और इस बाज़ार के समाधान में कोई भूमिका नहीं निभाता। · अपडेट किया गया
बाहरी लिंक से सावधान रहें।
बाहरी लिंक से सावधान रहें।
अक्सर पूछे जाने वाले प्रश्न